Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

OBJECTIVES: To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical efficacy in various patient subsets. METHODS: The BLISS trials compared belimumab 1 and 10 mg/kg versus pl...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vollenhoven, Ronald F, Petri, Michelle A, Cervera, Ricard, Roth, David A, Ji, Beulah N, Kleoudis, Christi S, Zhong, Z John, Freimuth, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396451/
https://www.ncbi.nlm.nih.gov/pubmed/22337213
http://dx.doi.org/10.1136/annrheumdis-2011-200937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396451/
https://www.ncbi.nlm.nih.gov/pubmed/22337213
http://dx.doi.org/10.1136/annrheumdis-2011-200937

Ejemplares similares